Top 10 Takeover kicks off its 11th year: How to get tickets for dining series at Leña
The Detroit Free Press and Metro Detroit Chevy Dealers recently unveiled the 2025 Restaurant of the Year, Restaurant of the Year Classic and 10 Best New Restaurants and Experiences in metro Detroit.
And with that, the popular Top 10 Takeover dining series featuring these restaurants is kicking off.
The dining series is in its 11th year showcasing the top metro Detroit restaurants and dining experiences named by Detroit Free Press dining critic Lyndsay C. Green.
What's unique about each experience is diners get an exclusive and personal interaction at the restaurant or establishment. Typically, the experiences take place as a private event and, at times, when the restaurant is closed.
Starting Thursday, ticket sales kick off for the first stop in this year's dining series: Lena on May 1.
Seatings are at 5 p.m. and 7:30 p.m. and diners will enjoy a four course, chef curated meal at Leña, a Brush Park neighborhood spot.
Leña, with its Spanish influence and wood-fired cooking, landed in the No. 2 spot on the 2025 Detroit Free Press/Metro Detroit Chevy Dealers Top 10 New Restaurants & Dining Experiences.
'When a restaurant draws inspiration from a particular country or region, it can be difficult not to veer into kitschy territory,' wrote Green. 'Leña, the new Brush Park neighborhood restaurant with Spanish influence, strikes a beautiful balance.'
Tickets for the meal are $90 per person and include a uniquely curated menu, gratuity, and tax.
Since the inception of the dining series, the Free Press and Metro Detroit Chevy Dealers have maintained a charitable aspect. That effort continues this year with $3 of each ticket sale donated to Forgotten Harvest to help fight food insecurity in metro Detroit.
More: No. 2: Leña in Detroit offers Spanish flair without usual suspects
Tickets for the series go on sale every other Thursday when Free Press subscribers have first access to tickets for each event. Subscribers should check their email at noon on Thursday for a link to ticket sales. Following subscriber sales, tickets for the general public go on sale at noon Friday at freep.com/top10 where you will also find a schedule of upcoming dining events.
Wagyu beef tongue, pearl onion
Cornmeal brioche, sofrito, dual anchovies
Provençal white asparagus, manchego sauce, jamon serrano, hazelnuts
Marinated pork coppa, wheat berries, peas, cabbage
Torrijas: Spanish-style French toast dessert
The vegetarian menu includes:
Grilled romanesco, salsa verde, harissa
Provençal white asparagus, manchego sauce, hazelnuts
Grilled maitake mushrooms, hazelnut romesco, chickpea panisse
Torrijas: Spanish-style French toast dessert
As in years past, the Metro Detroit Chevy Dealers are once again offering a contest for a chance for one diner to win two complimentary tickets to each dinner of the series, starting with Leña. You can enter the contest at chevydetroit.com.
Contact Detroit Free Press food and restaurant writer Susan Selasky and send food and restaurant news and tips to: sselasky@freepress.com. Follow @SusanMariecooks on Twitter. Subscribe to the Free Press.
This article originally appeared on Detroit Free Press: How to get tickets to the Top 10 Takeover dining series at Leña
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
4 hours ago
- CNBC
European stocks poised to move lower as trade tensions and U.S. economy remain in focus
Good morning from London. European stocks look set to turn lower in the last trading session of the week, as investors around the world await more key data for clues on the shape of the U.S. economy. FTSE 100 futures are currently 0.1% lower, while futures tied to the French CAC 40 and Germany's DAX are down by 0.4% and 0.1%, respectively. Regional stocks ended Thursday's session higher after the European Central Bank trimmed interest rates in a widely anticipated move. U.S. nonfarm payrolls data is due to be published later on Friday, with economists expecting a contraction in jobs from the previous month. Trade tensions are also still in focus for global investors after U.S. President Donald Trump spoke with his Chinese counterpart Xi Jinping on Thursday. Trump said the 90-minute call was "very good" and "almost entirely" focused on trade. — Chloe Taylor Overnight in Asia, stocks have been trading in mixed territory as investors digest the news that Trump and Xi held what the U.S. President described as a "very good" call. On Wall Street, U.S. stock futures are trading higher ahead of May's nonfarm payrolls data. — Chloe Taylor
Business Insider
5 hours ago
- Business Insider
Sanofi (SNY) Takes Bold $9.5Bn Immunology Leap
Sanofi (SNY) has its hands full—in the best way possible—after announcing its $9.5 billion acquisition of Blueprint Medicines. This marks the French pharma giant's fourth major strategic acquisition this year, but this deal stands out. Sanofi isn't just picking up a drug or two; it's gaining access to a robust immunology pipeline of internally developed therapies. In addition to securing Ayvakit, a treatment for systemic mastocytosis, the acquisition reinforces Sanofi's shift toward high-value biopharma assets. Despite recent stock underperformance, this bold move strengthens my long-term bullish outlook on Sanofi. Confident Investing Starts Here: Sanofi's Strategic Pivot Towards High-Value Biopharma Sanofi's recent sale of Opella, its consumer healthcare division, highlights a broader strategic shift toward prioritizing high-margin biopharma operations. The company has seen major success with Dupixent—a blockbuster drug for inflammatory conditions like COPD and dermatitis, which generated over $13 billion in sales last year and now makes up nearly 30% of Sanofi's total revenue. This move underscores Sanofi's commitment to doubling down on its most profitable and innovative drug assets. Immediate Ayvakit Revenue Sanofi's acquisition of Blueprint, while a sizable investment, brings immediate benefits in both revenue diversification and pipeline strength. Ayvakit, approved for treating advanced systemic mastocytosis (AdvSM) in 2021 and indolent systemic mastocytosis (ISM) in 2023, addresses a rare disease with few treatment options. The drug generated $479 million in 2024, and Blueprint projected up to $720 million in revenue for 2025. With peak annual sales expected to reach around $2 billion before 2030, Ayvakit offers Sanofi a strong, near-term revenue driver, helping to de-risk the $9.1 billion upfront cost. Strategically, it's also a seamless addition to Sanofi's growing immunology portfolio. Boosting Sanofi's Immunology Future with Blueprint's Pipeline While Blueprint's pipeline includes several candidates, the spotlight is on two key assets: elenestinib and BLU-808. Elenestinib is a next-generation KIT D816V inhibitor currently in late-stage development for systemic mastocytosis (SM). It aims to improve upon the safety profile of Ayvakit, potentially appealing to patients who may avoid Ayvakit due to side effects such as fatigue and cognitive impairment, thereby expanding Sanofi's market share in SM. BLU-808, on the other hand, is an early-stage asset targeting a broader range of inflammatory conditions, including allergic asthma and allergic rhinoconjunctivitis. Unlike SM, these are far more prevalent diseases, offering significantly larger commercial opportunities. Importantly, BLU-808 is tied to two contingent value rights (CVRs), which are dependent on achieving specific development and regulatory milestones. These CVRs provide a layer of downside protection for Sanofi—if BLU-808 fails in clinical trials, the company's overall payout for the asset is reduced. Navigating Margin Pressures with Strategic Investment All of this comes against the backdrop of ongoing margin pressures for Sanofi. The company has already walked back its 2025 operating margin target of 32%, citing pricing pressures in its legacy general medicines segment and a ramp-up in R&D spending. While Sanofi remains active in diabetes with drugs like Lantus and Toujeo, these products now face significant pricing headwinds from generics, making them far less profitable than they once were. The Blueprint acquisition underscores Sanofi's renewed focus on innovation and high-margin biopharma assets. Though this pivot comes at the cost of near-term margin dilution, it reflects a longer-term strategy: investing in R&D today in hopes of developing the next wave of blockbuster therapies. In this context, Sanofi is clearly still in the midst of a strategic transformation—one currently anchored by the strong performance of Dupixent. Unlike previous 'bolt-on' deals that added just a drug or two, the Blueprint acquisition marks a more decisive step toward reshaping Sanofi's portfolio around premium, next-generation therapeutics. What is the Price Prediction for SNY Stock? On Wall Street, SNY sports a consensus Moderate Buy rating based on two Buy, three Hold, and zero Sell ratings in the past three months. Sanofi's average stock price target of $62.20 implies ~25% upside potential over the next 12 months. Last week, analyst Sachin Jain from Bank of America Securities maintained a Buy rating on SNY. The analyst was bullish on Sanofi's pipeline, particularly itepekimab, despite it failing in one of two Phase 3 trials for COPD. Moreover, he noted that 'Sanofi's low price-to-earnings ratio, reflecting limited pipeline upside, is seen as an opportunity given the promising data from these trials, indicating a potential R&D turnaround for the company.' Blueprint Deal Seals the Verdict on SNY In summary, Sanofi's acquisition of Blueprint offers both near-term revenue and long-term growth potential. Ayvakit serves as a valuable bolt-on asset, while pipeline candidates like elenestinib and BLU-808 significantly enhance Sanofi's immunology portfolio. More importantly, the deal reflects Sanofi's strategic pivot toward higher-margin biopharma assets at a time when older drugs like Lantus are facing profitability headwinds. Though the investment may pressure margins in the short run, it sets the stage for long-term growth in a high-value segment of the pharmaceutical market. Notably, the deal is expected to be EPS accretive by 2027, thanks to Ayvakit's revenue potential, which will help justify and offset a large portion of the upfront $9.5 billion cost. Overall, Sanofi has secured a promising set of assets at a reasonable valuation while extending its leadership in immunology beyond Dupixent. With a modest P/E ratio of 20.5 and a solid 3.27% dividend yield, SNY stands out as a compelling long-term investment opportunity for investors seeking to tap into the expanding biopharmaceutical space.
Yahoo
6 hours ago
- Yahoo
Beyond Yoga Puts Lululemon and Athleta on Notice With Bigger Store Format
Beyond Yoga is stepping out, cutting the ribbon on a bigger store concept in Greenwich, Conn., on Friday and preparing an assortment that really lives up to its name. It's Beyond Yoga's first brick-and-mortar store on the East Coast and a big moment for the brand, which Levi Strauss & Co. bought in 2021 and which is now being prepped for a growth spurt that would put it into direct competition with Lululemon and Athleta at scale. More from WWD Revenue Rises at Lululemon in Q1, CEO Calvin McDonald Bullish Despite Cautious U.S. Consumer Why TikTok Can't Stop Talking About Lululemon's 2-in-1 Dress and Its Styling Frenzy With Shoes: The $148 Debate, Explained Authentic Brands Group Is Buying Dockers for $311 Million Leading the way is Nancy Green, who oversaw Athleta as it grew from 39 to 175 stores and has been putting that experience to work since becoming Beyond Yoga's chief executive officer last year. Green has been using her own particular blend of art and science to set the brand up for its next step. The arrival in Greenwich, for instance, is no accident. The company knows from its e-commerce business that the greater New York area is its largest market and used that data to guide it to the wealthy enclave. 'There's a big intuitive piece to this too,' Green told WWD. 'There's the data on where the bulk of our customer fans are currently, and then there's intuition. Does that make sense? Does that feel right? Because you can go into a market and there's multiple places you could open. We're opening in Boston [this year] and we can see where that customer bubble is in the Boston area. And there's multiple choices where we could go. We're going to Seaport because we stand there, we watch, we see our customer walking the streets. 'The other piece that's important is, Does the space feel right? That's also intuitive,' she said. 'Maybe it's not the right location or you need to wait for the right location. We're not going to go in just because the data shows us that that's probably where we should be.' Both sides of Green's brain aligned on the Greenwich store, a 2,760-foot-space that also has room to hold events and tap into that 'wellness-forward lifestyle' customer the brand targets. 'It's gorgeous,' Green said. 'Light oak floors, very natural elements and a lot of wood, a lot of very organic shapes, curves. The main reason for the larger format is that the line is expanding quite a bit. We needed a larger space to showcase the breadth of the assortment and to really just show the best expression of the brand. We're also [planning to use] these new spaces as community hubs, whether it's fitness events that we do in the store, community events, whatever is right for that store. We create very strong local partnerships with various studios.' The store comes with a new logo and is at the vanguard of a bigger rollout — both in retail and in terms of Beyond Yoga's assortment, which all includes or ties back to its signature Spacedye fabric. While the 20-year-old business has long had workout-ready gear and dresses, the collection has been growing rapidly lately. Puffer jackets were added last year. In August, the assortment reaches out more with wide-leg bottoms, vegan leather, sweaters, cashmere wool blends, varsity-inspired prep looks, styles for the trail and more. Beyond Yoga is done tiptoeing and is going even further beyond yoga with more looks that work from the studio to work to the street to the airport and everywhere else. 'First and foremost, we are a lifestyle brand that serves an active woman and man's lifestyle,' Green said. 'So we think about what are the things that they do? What do they need? Well, it starts with the activities that they do.' With the Greenwich opening, Beyond Yoga has eight doors and is expanding to 14 by the end of the year. Earlier this year Green said the brand could have 'at least 200 stores' over time. 'This is our 2.0 in stores,' Green said of the Greenwich location. 'This is a new concept. We are going to test it and we are going to nail it. We have to iterate and tweak some things as we learn and then we nail it and then we scale it. So test, iterate, nail it and scale it.' Best of WWD Macy's Is Closing 66 Stores in 2025 — Here's the List, Live Updates Inside the Demise of Lord & Taylor COVID-19 Spikes Elevate Retail Concerns
